In a previous study, it was found that the circulating level of IGFBP2 was elevated specifically in F4 stage fibrosis patients with chronic hepatitis C (CHC) but showed no significant changes in F0–F3 stages (27). Here, IGFBP2 is linked to chronic hepatitis C virus infection.